ES2588190T3 - Utilización de ácido hialurónico para la preparación de composiciones destinadas a la mejora de la función de protección de la piel, del ojo y de las mucosas - Google Patents

Utilización de ácido hialurónico para la preparación de composiciones destinadas a la mejora de la función de protección de la piel, del ojo y de las mucosas Download PDF

Info

Publication number
ES2588190T3
ES2588190T3 ES08827623.3T ES08827623T ES2588190T3 ES 2588190 T3 ES2588190 T3 ES 2588190T3 ES 08827623 T ES08827623 T ES 08827623T ES 2588190 T3 ES2588190 T3 ES 2588190T3
Authority
ES
Spain
Prior art keywords
hyaluronic acid
eye
intestinal mucosa
daltons
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08827623.3T
Other languages
English (en)
Spanish (es)
Inventor
Anthony Bresin
Edith Puchelle
Jean-Marie Zahm
Magali Milliot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Agro Industrie Recherches et Developpements ARD
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Agro Industrie Recherches et Developpements ARD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Agro Industrie Recherches et Developpements ARD filed Critical Institut National de la Santé et de la Recherche Médicale
Application granted granted Critical
Publication of ES2588190T3 publication Critical patent/ES2588190T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ES08827623.3T 2007-07-23 2008-07-04 Utilización de ácido hialurónico para la preparación de composiciones destinadas a la mejora de la función de protección de la piel, del ojo y de las mucosas Active ES2588190T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0705349 2007-07-23
FR0705349A FR2919185B1 (fr) 2007-07-23 2007-07-23 Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de l'etat des muqueuses
PCT/FR2008/000959 WO2009024677A2 (fr) 2007-07-23 2008-07-04 Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de la fonction de protection de la peau, de l'oeil et des muqueuses

Publications (1)

Publication Number Publication Date
ES2588190T3 true ES2588190T3 (es) 2016-10-31

Family

ID=39088885

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08827623.3T Active ES2588190T3 (es) 2007-07-23 2008-07-04 Utilización de ácido hialurónico para la preparación de composiciones destinadas a la mejora de la función de protección de la piel, del ojo y de las mucosas

Country Status (9)

Country Link
US (1) US8895532B2 (cg-RX-API-DMAC7.html)
EP (1) EP2167102B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010534225A (cg-RX-API-DMAC7.html)
KR (1) KR20100059786A (cg-RX-API-DMAC7.html)
CN (1) CN101801391B (cg-RX-API-DMAC7.html)
BR (1) BRPI0814446A2 (cg-RX-API-DMAC7.html)
ES (1) ES2588190T3 (cg-RX-API-DMAC7.html)
FR (1) FR2919185B1 (cg-RX-API-DMAC7.html)
WO (1) WO2009024677A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024194437A1 (en) * 2023-03-22 2024-09-26 Institut National de la Santé et de la Recherche Médicale Use of low molecular weight hyaluronic acid for promoting ciliated cell differentiation

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003797A1 (en) * 2008-07-09 2010-01-14 Novozymes Biopharma Dk A/S Hyaluronic acid for corneal wound healing
FR2963240B1 (fr) * 2010-07-28 2013-03-15 Horus Pharma Composition a usage topique sans conservateur comprenant de l'acide hyaluronique
RU2624239C2 (ru) 2011-06-03 2017-07-03 Аллерган, Инк. Составы кожного наполнителя, включая антиоксиданты
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
HUE037474T2 (hu) * 2011-07-07 2018-08-28 Holy Stone Healthcare Co Ltd Készítmény gyulladással kapcsolatban rendellenesség kezelésében és megelõzésében történõ alkalmazásra
TWI466675B (zh) 2011-09-16 2015-01-01 Univ China Medical 用於抑制發炎之醫藥組合物
CN102669681A (zh) * 2012-06-09 2012-09-19 东莞市照燕生物科技有限公司 一种保护胃肠粘膜的营养保健品
WO2014063735A1 (en) 2012-10-25 2014-05-01 Mdt Int'l S.A. Mucoadhesive compositions comprising hyaluronic acid and chitosan for topical application
JP2015063510A (ja) * 2013-06-28 2015-04-09 キユーピー株式会社 肌の保湿機能向上に関わる保湿関連遺伝子発現促進剤
EP3328353B1 (en) 2015-07-27 2024-04-10 Mary Kay, Inc. Topical skin formulations
JP6718728B2 (ja) * 2016-04-06 2020-07-08 キユーピー株式会社 アンチポリューション剤およびアンチポリューション用皮膚外用組成物
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
WO2022236585A1 (zh) * 2021-05-10 2022-11-17 傅毓秀 玻尿酸用于制备治疗肺纤维化药剂的用途
TWI816119B (zh) * 2021-05-10 2023-09-21 國立陽明交通大學 玻尿酸用於製備治療急性呼吸窘迫症藥劑之用途
WO2022236599A1 (zh) * 2021-05-10 2022-11-17 傅毓秀 玻尿酸用于制备治疗急性呼吸窘迫症药剂的用途
CN115317504A (zh) * 2021-05-10 2022-11-11 傅毓秀 玻尿酸用于制备治疗急性呼吸窘迫症药剂的用途
EP4426317A1 (en) * 2021-11-05 2024-09-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of low molecular weight hyaluronic acid for the treatment of lung mucosal inflammation
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4517295A (en) * 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
JPS59219209A (ja) * 1983-05-28 1984-12-10 Kanebo Ltd 皮膚化粧料
IT1260148B (it) * 1992-04-17 1996-03-28 Fidia Spa Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo
ITPD980168A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Composizioni biocompatibili e biodegradabili comprendenti acido ialuronico e suoi derivati per il trattamento delle ulcere dell'appara
DE10111165A1 (de) * 2001-03-02 2002-10-10 Knoell Hans Forschung Ev Verwendung von Hyaluronsäure-Uroniden zur Behandlung von entzündlichen Vorgängen
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
DE10161110A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
FR2847818B1 (fr) * 2002-11-28 2008-04-04 Agro Ind Rech S Et Dev Ard Composition pharmaceutique a base d'acide hyaluronique
WO2006072243A1 (en) * 2005-01-03 2006-07-13 Novozymes Biopolymer A/S Hyaluronic acid fraction with moisturizing and anti-wrinkle properties
JP4576583B2 (ja) * 2005-03-22 2010-11-10 キユーピー株式会社 ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024194437A1 (en) * 2023-03-22 2024-09-26 Institut National de la Santé et de la Recherche Médicale Use of low molecular weight hyaluronic acid for promoting ciliated cell differentiation

Also Published As

Publication number Publication date
US8895532B2 (en) 2014-11-25
CN101801391A (zh) 2010-08-11
HK1145149A1 (en) 2011-04-08
WO2009024677A3 (fr) 2009-12-03
JP2010534225A (ja) 2010-11-04
BRPI0814446A2 (pt) 2015-01-06
FR2919185B1 (fr) 2010-09-10
EP2167102B1 (fr) 2016-05-25
KR20100059786A (ko) 2010-06-04
EP2167102A2 (fr) 2010-03-31
CN101801391B (zh) 2013-07-10
US20100210585A1 (en) 2010-08-19
FR2919185A1 (fr) 2009-01-30
WO2009024677A2 (fr) 2009-02-26

Similar Documents

Publication Publication Date Title
US8895532B2 (en) Use of hyaluronic acid for the preparation of compositions intended for improving in particular the protective function of the skin, the eye and the mucous membranes
Kong et al. Restore intestinal barrier integrity: an approach for inflammatory bowel disease therapy
ES2773017T3 (es) Derivados de quitosano para el tratamiento de mucositis o ulceración
Antwi et al. Stigmasterol Modulates Allergic Airway Inflammation in Guinea Pig Model of Ovalbumin‐Induced Asthma
EP2545925B1 (en) Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases
Barroso et al. Propolis reversed cigarette smoke-induced emphysema through macrophage alternative activation independent of Nrf2
TWI913236B (zh) 新多功能寡肽
Takhshid et al. The healing effect of licorice extract in acetic acid-induced ulcerative colitis in rat model
Wigenstam et al. Acute respiratory changes and pulmonary inflammation involving a pathway of TGF-β1 induction in a rat model of chlorine-induced lung injury
ES2527096T3 (es) Combinación de ADNasa I y glucosaminoglucanos para su uso en limpieza de ADN extracelular
CN104292305B (zh) 一种多肽、制备方法及其应用
Xi et al. Establishment and characterization of murine models of asthma and subcutaneous immunotherapy for Humulus pollen allergy
Allon et al. Inhalation exposure to sulfur mustard in the guinea pig model: clinical, biochemical and histopathological characterization of respiratory injuries
Chen et al. Unraveling the mechanisms underlying air pollution-induced dysfunction of the oral–gut–brain axis: implications for human health and well-being
CN111135141A (zh) 一种鼻腔用复合水凝胶制备方法
Di Cicco et al. Hyaluronic acid for the treatment of airway diseases in children: Little evidence for few indications
ES2315479T3 (es) Empleo de glicosaminoglicanos tales como p.ej.heparina para el tratamiento de trastornos respiratorios tales como copd.
TWI480044B (zh) A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution
ES2754436T3 (es) Composiciones y métodos para usar cuerpos laminares para propósitos terapéuticos
CN112074291A (zh) 预防和治疗呼吸道疾病的组合物
Bentivegna et al. The linkage between upper respiratory tract infections and otitis media: evidence of the ‘united airways concept
Zeitlin et al. Protein processing and degradation in pulmonary health and disease
Qiu et al. Nrf2 Improves Airway Goblet Cell Metaplasia in Chronic Obstructive Pulmonary Disease (COPD) and Its Mechanism
HK1145149B (en) Use of hyaluronic acid for preparing compositions for improving the function of skin, eye and mucous membrane protection
US10035821B2 (en) Calcium binding compounds based on gamma-carboxy glutamate